Work

Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?

Year: 2025

Type: article

Abstract: A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.

Source: Trends in cancer

DOI: 10.1016/j.trecan.2025.05.004

Author: John B. Haanen

Institutions: Leiden University Medical Center, Centre Hospitalier Universitaire Vaudois, The Netherlands Cancer Institute

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,030